Wedbush Reiterates Outperform on Astria Therapeutics, Maintains $22 Price Target
Portfolio Pulse from Benzinga Newsdesk
Wedbush analyst Laura Chico reiterates an Outperform rating on Astria Therapeutics (NASDAQ:ATXS) and maintains a $22 price target.

May 10, 2024 | 1:36 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Wedbush analyst Laura Chico reaffirmed an Outperform rating on Astria Therapeutics with a $22 price target, indicating a positive outlook on the stock.
The reiteration of an Outperform rating and maintenance of a $22 price target by a reputable analyst like Laura Chico from Wedbush could instill confidence among investors and potentially drive the stock price up in the short term. Analyst ratings, especially from well-regarded financial institutions, can significantly influence investor sentiment and stock prices.
CONFIDENCE 90
IMPORTANCE 85
RELEVANCE 100